CIR Trademark
Trademark Overview
On Monday, July 17, 2023, a trademark application was filed for CIR with the United States Patent and Trademark Office. The USPTO has given the CIR trademark a serial number of 98088355. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, June 25, 2024. This trademark is owned by NKILT Therapeutics, Inc.. The CIR trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; living cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; biological preparations in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; therapeutic pharmaceuticals utilizing cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages in the treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; cell preparations such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological ...
Chemical and biochemical preparations for scientific purposes, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for laboratory and experimentation purposes, in particular for conducting experimental assays, other than for medical or veterinary purposes; reagents for scientific and research use, namely, reagents such as proteins and nucleic acids for modifying cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages
Medical services, in particular in the field of immunotherapy, in particular in the field of immuno-oncology; medical services in the field of hyperproliferative diseases; medical services in the field of cancer; medical services in the field of anti-infectives; in particular all of the aforesaid services related to the use of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages
Scientific and technological services, namely, scientific research, analysis and testing in the field of biology, pharmaceuticals and cell therapy; biological research and development; medical, pharmaceutical and biotechnological research
General Information
| Serial Number | 98088355 |
| Word Mark | CIR |
| Filing Date | Monday, July 17, 2023 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, June 25, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 30, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; living cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; biological preparations in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; therapeutic pharmaceuticals utilizing cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages in the treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; cell preparations such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections |
| Goods and Services | Chemical and biochemical preparations for scientific purposes, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for laboratory and experimentation purposes, in particular for conducting experimental assays, other than for medical or veterinary purposes; reagents for scientific and research use, namely, reagents such as proteins and nucleic acids for modifying cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages |
| Goods and Services | Medical services, in particular in the field of immunotherapy, in particular in the field of immuno-oncology; medical services in the field of hyperproliferative diseases; medical services in the field of cancer; medical services in the field of anti-infectives; in particular all of the aforesaid services related to the use of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages |
| Goods and Services | Scientific and technological services, namely, scientific research, analysis and testing in the field of biology, pharmaceuticals and cell therapy; biological research and development; medical, pharmaceutical and biotechnological research |
Classification Information
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 15, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 15, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 15, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 15, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | NKILT Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Springfield, NJ 07081 |
| Party Name | NKILT Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Springfield, NJ 07081 |
Trademark Events
| Event Date | Event Description |
| Thursday, July 20, 2023 | NEW APPLICATION ENTERED |
| Tuesday, August 15, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, March 22, 2024 | ASSIGNED TO EXAMINER |
| Monday, March 25, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 30, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 25, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, April 30, 2024 | PUBLISHED FOR OPPOSITION |
| Monday, March 31, 2025 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Monday, December 16, 2024 | SOU TEAS EXTENSION RECEIVED |
